Anti-MRFL/ MYRFL/ C12orf15 functional antibody

Anti-MRFL/ MYRFL/ C12orf15 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to MYRFL/MYRFL products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0360-Ab-1/ GM-Tg-hg-SE0360-Ab-2Anti-Human MYRFL monoclonal antibodyHuman
GM-Tg-rg-SE0360-Ab-1/ GM-Tg-rg-SE0360-Ab-2Anti-Rat MYRFL monoclonal antibodyRat
GM-Tg-mg-SE0360-Ab-1/ GM-Tg-mg-SE0360-Ab-2Anti-Mouse MYRFL monoclonal antibodyMouse
GM-Tg-cynog-SE0360-Ab-1/ GM-Tg-cynog-SE0360-Ab-2Anti-Cynomolgus/ Rhesus macaque MYRFL monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0360-Ab-1/ GM-Tg-felg-SE0360-Ab-2Anti-Feline MYRFL monoclonal antibodyFeline
GM-Tg-cang-SE0360-Ab-1/ GM-Tg-cang-SE0360-Ab-2Anti-Canine MYRFL monoclonal antibodyCanine
GM-Tg-bovg-SE0360-Ab-1/ GM-Tg-bovg-SE0360-Ab-2Anti-Bovine MYRFL monoclonal antibodyBovine
GM-Tg-equg-SE0360-Ab-1/ GM-Tg-equg-SE0360-Ab-2Anti-Equine MYRFL monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0360-Ab-1/ GM-Tg-hg-SE0360-Ab-2; GM-Tg-rg-SE0360-Ab-1/ GM-Tg-rg-SE0360-Ab-2;
GM-Tg-mg-SE0360-Ab-1/ GM-Tg-mg-SE0360-Ab-2; GM-Tg-cynog-SE0360-Ab-1/ GM-Tg-cynog-SE0360-Ab-2;
GM-Tg-felg-SE0360-Ab-1/ GM-Tg-felg-SE0360-Ab-2; GM-Tg-cang-SE0360-Ab-1/ GM-Tg-cang-SE0360-Ab-2;
GM-Tg-bovg-SE0360-Ab-1/ GM-Tg-bovg-SE0360-Ab-2; GM-Tg-equg-SE0360-Ab-1/ GM-Tg-equg-SE0360-Ab-2
Products NameAnti-MYRFL monoclonal antibody
Formatmab
Target NameMYRFL
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-MYRFL benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0360-Ag-1Recombinant multi-species MRFL/ MYRFL/ C12orf15 protein


    Target information

    Target IDGM-SE0360
    Target NameMYRFL
    Gene ID196446,237558,362879,717240,102153182,101100399,781109,100062967
    Gene Symbol and Synonymsbcm1377,C12orf15,C12orf28,C5H12orf28,CB4H12orf28,Gm239,MYRFL,RGD1562127
    Uniprot AccessionQ96LU7,F1N4M2
    Uniprot Entry NameMRFL_HUMAN,MRFL_BOVIN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000166268
    Target ClassificationN/A

    The target: MYRFL, gene name: MYRFL, also named as C12orf15, C12orf28, bcm1377. Predicted to enable DNA-binding transcription factor activity and sequence-specific DNA binding activity. Predicted to be involved in positive regulation of transcription, DNA-templated and protein autoprocessing. Predicted to be integral component of membrane. Predicted to be active in endoplasmic reticulum membrane and nucleus. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.